US 12,011,477 B2
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
Andrea Fritzer, Vienna (AT); Andreas Meinke, Pressbaum (AT); Urban Lundberg, Pressbaum (AT); Mario Nebenführ, Vienna (AT); Jürgen Heindl-Wruss, Vienna (AT); Robert Schlegl, Siegenfeld (AT); and Arnaud Leon, Nantes (FR)
Assigned to Valneva SE, Nantes (FR)
Filed by Valneva SE, Nantes (FR)
Filed on Sep. 26, 2022, as Appl. No. 17/935,490.
Application 17/935,490 is a continuation of application No. 16/641,012, granted, now 11,484,587, previously published as PCT/EP2018/075392, filed on Sep. 19, 2018.
Claims priority of application No. 17192374 (EP), filed on Sep. 21, 2017.
Prior Publication US 2023/0293661 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); C12N 2770/36121 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36123 (2013.01); C12N 2770/36134 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising CHIKV-Δ5nsP3 particles, wherein said composition comprises
(i) at least 103 CHIKV-Δ5nsP3 particles which express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2 and;
(ii) 1-70% CHIKV-Δ5nsP3 particles which express an E2 structural protein having one to ten mutations compared with the amino acid sequence of SEQ ID NO: 2.